These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 29947977)

  • 1. Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency-a case report and comprehensive review of the literature.
    Simonis A; Fux M; Nair G; Mueller NJ; Haralambieva E; Pabst T; Pachlopnik Schmid J; Schmidt A; Schanz U; Manz MG; Müller AMS
    Ann Hematol; 2018 Oct; 97(10):1961-1973. PubMed ID: 29947977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
    Grossman J; Cuellar-Rodriguez J; Gea-Banacloche J; Zerbe C; Calvo K; Hughes T; Hakim F; Cole K; Parta M; Freeman A; Holland SM; Hickstein DD
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1940-8. PubMed ID: 25111582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.
    Spinner MA; Sanchez LA; Hsu AP; Shaw PA; Zerbe CS; Calvo KR; Arthur DC; Gu W; Gould CM; Brewer CC; Cowen EW; Freeman AF; Olivier KN; Uzel G; Zelazny AM; Daub JR; Spalding CD; Claypool RJ; Giri NK; Alter BP; Mace EM; Orange JS; Cuellar-Rodriguez J; Hickstein DD; Holland SM
    Blood; 2014 Feb; 123(6):809-21. PubMed ID: 24227816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations.
    Mir MA; Kochuparambil ST; Abraham RS; Rodriguez V; Howard M; Hsu AP; Jackson AE; Holland SM; Patnaik MM
    Cancer Med; 2015 Apr; 4(4):490-9. PubMed ID: 25619630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation.
    Rajput RV; Arnold DE
    Curr Hematol Malig Rep; 2023 Aug; 18(4):89-97. PubMed ID: 37247092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-derived myelodysplastic syndrome after allogeneic stem cell transplantation in a family with germline GATA2 mutation.
    Sakata N; Okano M; Masako R; Tanaka A; Yamashita Y; Karasuno T; Imadome KI; Okada M; Sugimoto K
    Int J Hematol; 2021 Feb; 113(2):290-296. PubMed ID: 32865708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA2 Deficiency: Early Identification for Improved Clinical Outcomes.
    Cole K; Avila D; Parta M; Schuver B; Holland S; Shah N; Hickstein D
    Clin J Oncol Nurs; 2019 Aug; 23(4):417-422. PubMed ID: 31322613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generalized verrucosis in a patient with GATA2 deficiency.
    West ES; Kingsbery MY; Mintz EM; Hsu AP; Holland SM; Rady PL; Tyring SK; Grossman ME
    Br J Dermatol; 2014 May; 170(5):1182-6. PubMed ID: 24359037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation in the management of GATA2 deficiency and pulmonary alveolar proteinosis.
    van Lier YF; de Bree GJ; Jonkers RE; Roelofs JJTH; Ten Berge IJM; Rutten CE; Nur E; Kuijpers TW; Hazenberg MD; Zeerleder SS
    Clin Immunol; 2020 Sep; 218():108522. PubMed ID: 32682923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.
    Wlodarski MW; Hirabayashi S; Pastor V; Starý J; Hasle H; Masetti R; Dworzak M; Schmugge M; van den Heuvel-Eibrink M; Ussowicz M; De Moerloose B; Catala A; Smith OP; Sedlacek P; Lankester AC; Zecca M; Bordon V; Matthes-Martin S; Abrahamsson J; Kühl JS; Sykora KW; Albert MH; Przychodzien B; Maciejewski JP; Schwarz S; Göhring G; Schlegelberger B; Cseh A; Noellke P; Yoshimi A; Locatelli F; Baumann I; Strahm B; Niemeyer CM;
    Blood; 2016 Mar; 127(11):1387-97; quiz 1518. PubMed ID: 26702063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
    Cuellar-Rodriguez J; Gea-Banacloche J; Freeman AF; Hsu AP; Zerbe CS; Calvo KR; Wilder J; Kurlander R; Olivier KN; Holland SM; Hickstein DD
    Blood; 2011 Sep; 118(13):3715-20. PubMed ID: 21816832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
    Kotmayer L; Romero-Moya D; Marin-Bejar O; Kozyra E; Català A; Bigas A; Wlodarski MW; Bödör C; Giorgetti A
    Br J Haematol; 2022 Nov; 199(4):482-495. PubMed ID: 35753998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation.
    Rastogi N; Abraham RS; Chadha R; Thakkar D; Kohli S; Nivargi S; Prakash Yadav S
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):e383-e388. PubMed ID: 29189513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful reduced-intensity stem cell transplantation for GATA2 deficiency before progression of advanced MDS.
    Saida S; Umeda K; Yasumi T; Matsumoto A; Kato I; Hiramatsu H; Ohara O; Heike T; Adachi S
    Pediatr Transplant; 2016 Mar; 20(2):333-6. PubMed ID: 26748574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA2 and marrow failure.
    Fabozzi F; Strocchio L; Mastronuzzi A; Merli P
    Best Pract Res Clin Haematol; 2021 Jun; 34(2):101278. PubMed ID: 34404529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA2 deficiency and haematopoietic stem cell transplantation: challenges for the clinical practitioner.
    Bogaert DJ; Laureys G; Naesens L; Mazure D; De Bruyne M; Hsu AP; Bordon V; Wouters E; Tavernier SJ; Lambrecht BN; De Baere E; Haerynck F; Kerre T
    Br J Haematol; 2020 Mar; 188(5):768-773. PubMed ID: 31710708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of GATA2-related myeloid neoplasms.
    Hirabayashi S; Wlodarski MW; Kozyra E; Niemeyer CM
    Int J Hematol; 2017 Aug; 106(2):175-182. PubMed ID: 28643018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.
    Lübking A; Vosberg S; Konstandin NP; Dufour A; Graf A; Krebs S; Blum H; Weber A; Lenhoff S; Ehinger M; Spiekermann K; Greif PA; Cammenga J
    Leuk Res Rep; 2015; 4(2):72-5. PubMed ID: 26716079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful umbilical cord blood hematopoietic stem cell transplantation in pediatric patients with MDS/AML associated with underlying GATA2 mutations: two case reports and review of literature.
    Mallhi K; Dix DB; Niederhoffer KY; Armstrong L; Rozmus J
    Pediatr Transplant; 2016 Nov; 20(7):1004-1007. PubMed ID: 27416790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.